Home

Home

Semen can worsen cervical cancer

UK - Cervical cancer could be aggravated by a hormone-like molecule – prostaglandin - found in semen, according to a team of scientists led by Dr Henry Jabbour at the Medical Research Council’s Human Reproductive Sciences Unit.

The researchers also found that the high concentration of prostaglandin in semen makes other diseases of the female reproductive organs worse - including uterine cancer. The team explained that prostaglandins in semen can influence the progression of cervical and uterine cancers by enhancing tumour growth.

Cells lining the female reproductive organs naturally produce prostaglandin, which helps to regulate cell growth (e.g. messages passed from cell to cell by prostaglandin molecules direct the womb lining to either thicken or shed during a menstrual cycle). However, the concentration of prostaglandin in seminal fluid is 1,000 times higher than that normally found in these cells.
Prostaglandin receptor molecules are present on the surface of cells that make up cervical and uterine cancer tumours. The influx of prostaglandin delivered by semen enhances the normal level of signalling between cells. The high volume starts new cascades of signals that eventually lead to an increase in tumour growth.  

Prostaglandins do not cause cervical cancer; it usually is triggered by long-term human papilloma virus infection. However, the MRC research shows that seminal fluid can contribute to tumour growth. ‘Sexually active women who are at risk of cervical or uterine cancer should encourage their partners to wear a condom to prevent increased exposure to the prostaglandins that might make their condition worse,’

Dr Jabbour cautioned. ‘It also highlights the potential for a new therapeutic approach that will tackle both possible sources of prostaglandin, those produced naturally by women and those introduced to the body by sperm.’

Search

 

Service

Company News

Technical infrastructure for EU funded R-bay project

Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.

Accu-Chek® Combo – put effective diabetes management into action

At the annual congress of the European Association for the Study of Diabetes (EASD) this year in Rome, Roche Diabetes Care introduced Accu-Chek Combo – the insulin pump system that combines an insulin pump with an intelligent glucose monitoring system, a bolus calculator, and an integrated pump remote-control.

Products redesigned to help patients simplify life with diabetes

Bayer HealthCare Diabetes Care unveiled the new
CONTOUR® blood glucose meter with enhanced testing features at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome, Italy.